{
    "2019-03-05": [
        [
            {
                "time": "2019-03-12",
                "original_text": "FDA's Scott Gottlieb Resigns â€” What's Next For Biotech, Pharma?",
                "features": {
                    "keywords": [
                        "FDA",
                        "Scott Gottlieb",
                        "Resigns",
                        "Biotech",
                        "Pharma"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-04-05",
                "original_text": "Novartis has no plans to sell Sandoz - chairman",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "no plans",
                        "sell"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-10",
                "original_text": "The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Psoriasis Drug",
                        "Superior",
                        "Ascendis",
                        "Offering",
                        "Adamas",
                        "Earnings"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}